
- /
- Supported exchanges
- / US
- / HALO.NASDAQ
Halozyme Therapeutics Inc (HALO NASDAQ) stock market data APIs
Halozyme Therapeutics Inc Financial Data Overview
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Halozyme Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Halozyme Therapeutics Inc data using free add-ons & libraries
Get Halozyme Therapeutics Inc Fundamental Data
Halozyme Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 179 M
- EBITDA: 759 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: 1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Halozyme Therapeutics Inc News

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors
In value investing, the search for undervalued stocks with strong basic foundations remains a central strategy. This approach, started by Benjamin Graham and later improved by investors like Warren Bu...


5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
Wall Street closed in the green yesterday, with all three major indexes inching higher. The Nasdaq Composite gained 0.45% to reach a record 21,798.70, while the S&P 500 added 0.21% to end at 6,495.15....

Does Halozyme Stock Offer More Potential After Its Recent Strong Price Run in 2025?
If you have been watching Halozyme Therapeutics lately, you are not alone, and the reason is clear: this biotech name has taken investors on quite the rewarding ride. Whether you are holding your shar...

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum
The method used to find good investment chances joins Mark Minervini’s strict Trend Template with a concentration on strong-growth momentum. Minervini’s method highlights stocks showing solid tech...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.